- MHCD0428 - Invitrogen Antibodies CD4 antibody

Submitted references A Biological Circuit Involving Mef2c, Mef2d, and Hdac9 Controls the Immunosuppressive Functions of CD4+Foxp3+ T-Regulatory Cells.

Di Giorgio E, Wang L, Xiong Y, Christensen LM, Akimova T, Han R, Samanta A, Trevisanut M, Brancolini C, Beier UH, Hancock WW
Frontiers in immunology 2021;12:703632

MEF2D sustains activation of effector Foxp3+ Tregs during transplant survival and anticancer immunity.

Di Giorgio E, Wang L, Xiong Y, Akimova T, Christensen LM, Han R, Samanta A, Trevisanut M, Bhatti TR, Beier UH, Hancock WW
The Journal of clinical investigation 2020 Dec 1;130(12):6242-6260

Inhibiting the coregulator CoREST impairs Foxp3+ Treg function and promotes antitumor immunity.

Xiong Y, Wang L, Di Giorgio E, Akimova T, Beier UH, Han R, Trevisanut M, Kalin JH, Cole PA, Hancock WW
The Journal of clinical investigation 2020 Apr 1;130(4):1830-1842

Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.

Patel MA, Kim JE, Theodros D, Tam A, Velarde E, Kochel CM, Francica B, Nirschl TR, Ghasemzadeh A, Mathios D, Harris-Bookman S, Jackson CC, Jackson C, Ye X, Tran PT, Tyler B, Coric V, Selby M, Brem H, Drake CG, Pardoll DM, Lim M
Journal for immunotherapy of cancer 2016;4:28

T-cell receptor repertoire of human peripheral CD161hiTRAV1-2+ MAIT cells revealed by next generation sequencing and single cell analysis.

Held K, Beltrán E, Moser M, Hohlfeld R, Dornmair K
Human immunology 2015 Sep;76(9):607-14

High content cellular immune profiling reveals differences between rhesus monkeys and men.

Magalhaes I, Vudattu NK, Ahmed RK, Kühlmann-Berenzon S, Ngo Y, Sizemore DR, Wehlin L, Weichold F, Andersson J, Skeiky YA, Sadoff J, Gaines H, Thorstensson R, Spångberg M, Maeurer MJ
Immunology 2010 Sep;131(1):128-40

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Human peripheral blood lymphocytes were stained using Pacific Blue of anti-human CD4 monoclonal antibody (clone S3.5). The negative control profiles represent unstained cells.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Flow Cytometry analysis using a CD4 monoclonal antibody (Product # MHCD0428).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 3 Tumor infiltrating lymphocytes (TIL) in the anti-GITR (1)/SRS group have a Th1 immunophenotype and elevated effector to Treg ratio. C57BL/6 mice were inoculated with GL261-luc tumor, randomized to groups of >=5, and dosed with anti-GITR (1) and SRS as in Fig. 1 . Mice were sacrificed on day 21, tumor infiltrating lymphocytes were isolated, cells were stimulated with PMA/Ionomycin, fixed, and permeabilized for staining of intracellular markers. a CD8+ and b CD4+ cell populations were analyzed by flow cytometry for expression of IFNgamma, TNFalpha, and IL-2. Intratumoral effector CD8+ and CD4+ to Treg ratios in the anti-GITR (1)/SRS group were calculated c . Symbol and horizontal bar denote single mouse and average value, respectively. * P < .05

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 Eradication of intracranial GL261 tumors with anti-GITR (1) mAb plus SRS combination therapy. C57/BL6 mice were intracranially inoculated with 1.3 x 10 5 GL261-luc cells, and after tumor establishment was confirmed by bioluminescence, mice were randomized into four groups of 10 mice per arm on day 7. Mice were administered focal radiation of 10 Gy 10 days after tumor implantation and/or received 200 mul anti-GITR (1) (10 mg/kg) by i.p. injection on days 10, 13, and 16 a . Mice were followed for survival b ; curve-adjacent asterisks compare indicated curve to control. Tumor size was followed with bioluminescent imaging c ; four representative mice are shown. Mice were sacrificed on day 21, and tumor infiltrating CD4 and CD8 T cells (gated on CD3+ cells) and Tregs (gated on CD4+ cells) were isolated and analyzed by flow cytometry d and e . Symbol and horizontal bar ( e ) denote single mouse and average value, respectively. * P < .05, ** P < .01, **** P < .0001

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 5 Lack of intracranial tumor eradication and Treg depletion with the anti-GITR IgG 2a antibody/SRS combination. C57BL/6 mice were intracranially inoculated with GL261-luc tumor, randomized to groups of >=8, and dosed with 200 mul of anti-GITR (2a) (10 mg/kg) on day 10, 13, 16 and/or SRS (10 Gy) on day 10. Mice were followed for survival, a and tumor growth was assessed by bioluminescent imaging b . Mice were sacrificed on day 21, tumor infiltrating Tregs were isolated and analyzed by flow cytometry c . CD11b + CD45+ tumor resident microglia and tumor infiltrating mononuclear cells were isolated on day 21, analyzed by flow cytometry (gated on CD3+ cells), and mean fluorescence intensity (MFI) of FcgammaRIII and IV expression was calculated d . Flank tumors were established in C57BL/6 mice by subcutaneous inoculation of 2 x 10 6 GL261-luc cells in a volume of 100 mul, and intracranial tumors were established as in Fig. 1 . Mice were dosed i.p with 200 mul of anti-GITR (2a) (10 mg/kg) on days 10, 13, and 16, sacrificed on day 17, and tumor infiltrating lymphocytes were harvested and analyzed by flow cytometry for FoxP3 expression (gated on CD3+ cells) e - f . Symbol and horizontal bar denote single mouse and average value, respectively. * P < .05, *** P < .001. NS, non-significant

MHCD0428

Antibody data